TargetBeta
IL1A
interleukin 1 alpha · also IL1F1, IL-1A, IL1-ALPHA, IL1 · Interleukins
3 programs in company-led studies act on IL1A, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Interleukin 1 Receptor Antagonist Proteinrule | Amgen | antagonist | phase 4 | 141 running | – | NCIt |
| lutikizumab | AbbVie | – | phase 3 | 128 running | IL1B | the company's pipeline |
| ABBV-1451 | AbbVie | – | phase 1 | 11 running | IL1B | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Arthritis, Rheumatoid, 2 programs
- Arthritis, Juvenile, 1 program
- Arthritis, Psoriatic, 1 program
- COVID-19, 1 program
- Crohn Disease, 1 program
- Familial Mediterranean Fever, 1 program
- Hidradenitis Suppurativa, 1 program
- Osteoarthritis, 1 program
- Still's Disease, Adult-Onset, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026lutikizumab · AbbVie · phase 3 · NCT06468228
- Apr 2027ABBV-1451 · AbbVie · phase 1 · NCT07570147
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.